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Abstract 
Increased interest in the clinical use of antibiotics for periodontal therapy required the development of a 
sensitive assay for the quantitation of levofloxacin in gingival crevicular fluid (GCF). The HPLC assay employs a C18 
reversed-phase Hypersil BDS column with a mobile phase composed of methanol and phosphate buffer (pH 3.5). The 
chromatographic separation was monitored by a UV- Visible detector with an excitation wavelength of 290nm. The 
retention time of Levofloxacin and Ciprofloxacin were 5.55 min and 6.52min respectively.  Levofloxacin was extracted 
from GCF collected on capillary tubes by addition of acetonitrile containing the internal standard ciprofloxacin, and 
phosphate buffer. The percentage mean extraction recovery of low, mid and high quality control samples was 89.53 ± 
0.91 % (Mean ± SD) for Levofloxacin and it was 91.2 ± 2.2 % for Ciprofloxacin. The lowest limit of quantitation was 
50 ng/ml, with a relative standard deviation of 2.56%. The interday and intraday precision at LLOQ was 3.20 ± 0.80 
(mean±SD) and 3.505 0.84 (mean±SD). The typical GCF volumes collected were 0.1-1 l. The method was validated 
for the linear concentration range 50-1300 ng/ml of levofloxacin on the capillary tubes. This assay for levofloxacin was 
shown to be an accurate, precise and rugged method. The proposed method can be used for the estimation of 
Levofloxacin which was administered as in situ gels in periodontitis. 
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1. Introduction 
Periodontitis is characterized by destruction of 
periodontal ligament, resorption of alveolar bone and 
migration of junctional epithelium along the root surface. 
Clinical symptoms of periodontitis include changes in the 
morphology of gingival tissues and bleeding up on 
probing. In such a condition, inner layer of the gum and 
bone recede from the teeth and form pockets. Concerns 
associated with the use of systemic antibiotics 
encouraged development of local drug delivery systems 
as a viable alternative over systemic agents. Levofloxacin 
(OFX) is a fluoroquinolone antimicrobial agent having a 
high antibacterial activity against gram positive and gram 
negative bacteria in vitro and in vivo [1]. Chemically, 
ofloxacin, a fluorinated carboxyquinolone, is the 
racemate, (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-
methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-
benzoxazine-6-carboxylic acid [2] (Fig. 1).  
 
Figure 1: Chemical structure of Levofloxacin 
 
The mechanism of the activity is based on the 
inhibition of the DNA-gyrase of the bacteria. In vitro 
studies had shown that OFX has early bactericidal 
activity against Mycobatcerium tuberculosis [3]. Due to 
the low flow rate of GCF, limited volumes are obtained 
(0.1-ll) thus assays measuring levels of drugs in this 
fluid must have a greater sensitivity than assays 
measuring drugs in serum or plasma [4-6]. Samples were 
collected from patients with periodontal disease using 
capillary tubes. 
Several high-performance liquid 
chromatography (HPLC) methods have been developed 
for measuring OFX concentration in body fluids, but 
literature survey revealed that no method was available 
for the determination of OFX in GCF [7-13]. Thus, the 
aim of this study was to develop and validate a simple 
and rapid HPLC assay for measuring OFX levels in 
gingival crevicular fluid that is free of interference. With 
lower limit of quantitation (LLOQ) of 50 ng/ml of 
levofloxacin on the capillary tubes with the excellent 
precision and accuracy. 
 
2. Experimental 
2.1. Materials and reagents 
 Levofloxacin was obtained as gift sample from 
Microlabs (Bangalore). Ciprofloxacin was obtained as gift 
sample from Microlabs (Bangalore) used as internal 
standard. Methanol, acetonitrile were supplied by 
Qualigen fine chemical (HPLC or ACS grade) and used 
for the mobile phase preparation and as diluents 
respectively. Disodium hydrogen phosphate, sodium 
dihydrogen phosphate and Ortho Phosphoric acid AR 
grade were supplied by S.D. Fine Chemicals (Mumbai),  
used for the mobile phase preparation. Standard solutions 
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were prepared using levofloxacin in acetonitrile and 
phosphate buffer. Drug free GCF and GCF containing 
drug were supplied by Government dental Hospital 
(Bangalore). Microcenterifuge tubes (Tarsons, Mumbai) 
(1.5 ml) used to spike the standard and QC samples. 
2.2. Apparatus 
A Shimadzu liquid chromatograph equipped 
with a model LC-10ADvp gradient pump, Rheodyne 
7725i injector with 20 l loop and model SPD-M10Avp 
UV-Visible detector was used for the analysis. The 
separation was performed on a Hypersil BDS C18 (250 
mm x 46 mm I.D.) column (Thermo, USA), with 5 m 
particle diameter. 
2.3. Preparation of solutions 
2.3.1. Preparation of the internal standard solution 
A 10 l ml-1 ciprlevofloxacin internal standard 
solution was accurately prepared in HPLC grade 
acetonitrile and phosphate buffer. 
2.3.2. Preparation of Standard solution  
A 10 g ml-1 levofloxacin reference standard 
solution was accurately prepared in HPLC grade 
Acetonitrile and phosphate buffer (levofloxacin stock). 
2.3.3. Clinical sample collection 
Samples were collected from patients with 
periodontal disease using capillary tubes. Extreme care 
was taken to minimize GCF contamination with tooth 
surface debris. To minimize that the tooth surface above 
the periodontal pocket collection site was wiped with a 
cotton swab to remove any debris. The GCF fluid flowed 
from the gingival pocket up the capillary tubes by 
capillary action. The lower portion of the capillary tube 
was placed between the jaws of the Periotron and a score 
was obtained. Sample volumes were determined by 
interpolation from a volume versus Periotron score 
calibration curve. GCF volumes were used to report 
levofloxacin as concentration per unit volume. Typical 
volumes obtained were between 0.1-1.0 l.  
2.4. Extraction procedure 
Samples were examined to verify the capillary 
tubes were at the bottom of the microcentrifuge tubes. 
The GCF standard and GCF samples were extracted 
using Ciprofloxacin internal standard solution (20 l) and 
Acetonitrile (1 ml) were added to each tube. Samples 
were vortexed for 30sec and centrifuged for 5 min at 
4000 rpm. The supernatant liquid was taken in a 100 l 
autosampler vials and injected into the HPLC. 
 
2.4.1. GCF standard curve 
GCF standard solutions were prepared using 10, 
20 and 30 g ml-1concentration of Levofloxacin from 
levofloxacin stock into that GCF, internal standard 
Ciprofloxacin, acetonitrile were added respectively. 
2.4.2 Quality control (QC) samples 
QC samples were made from different time 
intervals of GCF samples- 0hr, 1hr, 2hrs, 4hrs, 8hrs, 
16hrs, 4 days, 8days, 14days and 30 days respectively. 
The each time interval samples are spiked separately into 
100 l of acetonitrile from that 60l was taken into a 1.5 
ml micro centrifuge tubes followed by 20l of internal 
standard ciprofloxacin, 80l of phosphate buffer and 1ml 
of acetonitrile were added respectively. The prepared 
samples were vortexed for 30sec and centrifuged for 5 
min at 4000 rpm. The supernatant solution was taken in a 
100 l autosampler vials and injected into the HPLC. 
2.5. HPLC conditions 
The mobile phase consisted of methanol and a 
phosphate buffer containing 20mM disodium hydrogen 
phosphate and 20mM of sodium dihydrogen phosphate 
pH 3.5 adjusted with phosphoric acid (32:68 v/v) at a 
flow rate of 1 ml/min. The mobile phase was filtered 
through a 0.45 µ membrane filter (Sartorius, Germany) 
and degassed before analysis.  The injection volumes 
were 20 l and the run time was 15 min. The UV-Visible 
detector has an excitation wavelength of 290 nm.  
 
3. Results and discussion 
Three quality control pools were prepared LQC 
(QC1), MQC (QC2) and HQC (QC3) in pre-screened 
human serum and 1l was spiked to validate this method 
for OFX in GCF. All quality control samples and 
standard curve samples were prepared using human 
serum instead of GCF because GCF was not 
commercially available not easily collectible. 
3.1. Development of Chromatogram 
The chromatogram of sample containing only 
levofloxacin in figure 2 showed only one major peak at 
5.55 min. The chromatogram of a GCF sample of 
levofloxacin is shown in Fig. 2. The retention time of 
levofloxacin and ciprofloxacin was 5.55 and 6.52 min 
respectively. 
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Figure 2: Chromatogram showing levofloxacin and ciprofloxacin (IS) in GCF 
 
3.2. Linearity 
The linear range for OFX in human serum was 
validated using 6 standards in triplicate covering the 
range 50-1300 ng/ml of OFX. The lowest limit of 
quantitation was 50 ng/ml, with a relative standard 
deviation of 2.56%. Standard curves were generated 
using a weighted (l/x) linear least squares regression of 
the OFX peak area vs. concentration.  
Table 1 summarizes the correlation coefficients, 
slope, intercept and the pooled percent errors for all 
validation standard curves. The data demonstrates the 
linearity and the reproducibility of the standard curves 
for the developed method. 
 
 
 
 
 
Table 1: Results for summary of standard curve 
           Parameter             Value 
Correlation Co-efficient (r
2
)            0.9978 
Slop             0.5773 
Y-intercept          + 0.0421 
%RSD              2.56% 
3.3. Precision and accuracy 
The interday and intraday precision at LLOQ 
was 3.20 ± 0.80 (mean±SD) and 3.505 0.84(mean±SD). 
Table 2 summarizes the precision and accuracy results 
for the method. The precision (%R.S.D., relative standard 
deviation: (S.D./mean)x 100) for QC1, QC2, QC3 
concentrations were 8.36%, 1.25%, 0.58%, respectively. 
The accuracy (%REC, relative recoveries: (back 
calculated value/nominal value)x 100) for  QC1 QC2 and 
QC3 were within  1.00%. The accuracy of the method 
varies from 99.0 to 100.5% among all batches. 
Table 2: Results for Precision and accuracy of QC samples 
Conc.         Drug        IS area        Area ratio Pred. Conc. % Bias % REC 
 
Avg. area 
(n=6) 
%RSD 
 
Avg. 
Area (n=6) 
%RSD 
 
Avg. 
 
%RSD    
0.20 12975 8.6136 78949 0.5346 0.1643 8.3600 0.1982 -0.85228 99.10 
0.80 40301 1.2556 77708 0.5927 0.5186 1.7355 0.8029 0.372871 100.36 
1.60 75104 0.5803 76261 0.7617 0.9848 0.4459 1.5987 -0.0799 99.91 
 
3.4. Extraction Recovery 
The recovery was measured over the linear 
range of 1-25 g/ml of OFX by comparing a triplicate 
standard curve prepared in acetonitrile to a triplicate 
standard curve prepared in spiked serum. The results are 
shown in Table 3 and the percent extraction recovery for 
QC1, QC2, and QC3 was 87.92 %, 88.89 % and 90.76 % 
respectively. The percentage mean extraction recovery of 
low, mid and high quality control samples was 89.53 ± 
0.91 % (Mean ± SD) for Levofloxacin and it was 91.2 ± 
2.2 % for Ciprofloxacin. 
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Table 3: Results for Recovery study 
 
Unextracted drug Avg. area 
(n=3) 
Extracted drug Avg. area 
(n=3) 
% Extraction recovery 
QC1 64501.67 60280 93.45 
QC2 279770 253538.3 90.73 
QC3 1440640 1364623 94.72 
 
3.5. Specificity 
The specificity of the method was demonstrated 
by running chromatograms of drug free human serum 
sample. All chromatograms demonstrated no peaks 
which would interfere with the OFX or internal standard 
peaks. 
3.6. Stability study 
The method was also validated for its stability. 
The processed samples in the acetonitrile-buffer were 
stable at least 20 h at room temperature. The GCF 
samples were stable at least 3 weeks at -20°C with three 
thaw and freeze cycles. The mean nominal concentration 
of three freeze thaw cycles, short term stability (Sample 
processing time) and long term stability (-20° C for 2 
weeks) were 95.6 ± 0.28 %, 94.05 ± 0.21% and 96.2 ± 
0.42% respectively. 
3.7 Selectivity 
The selectivity of the method was performed by 
spiking the concentration of LLOQ at six different 
aliquots plasma samples and the regression equation was 
used for the quantitation of unknown samples. 
 
4. Conclusion 
The validated method for OFX in GCF 
described in this paper is precise, accurate and rugged 
and was shown to be sensitive. This method is suitable 
for use as the standard method for analysis of OFX in 
GCF for future products such as insitu gels and product 
modifications for the treatment of periodontal disease. 
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